A Review of the Global Burden of Antimicrobial Resistance: Trends, Challenges, and Future Directions

Research Article

Abstract

Antimicrobial resistance (AMR) poses a critical and escalating threat to global health, undermining the effectiveness of drugs used to prevent and treat infectious diseases. Driven by adaptive mechanisms in microorganisms, AMR compromises the efficacy of standard treatments, elevating the risks of disease spread, severe illness, and mortality. Recent estimates indicate that bacterial AMR was directly responsible for 1.27 million deaths globally in 2019, with a disproportionate burden in low- and middle-income countries (LMICs) due to limited access to diagnostics, effective antimicrobials, and resilient healthcare systems. The emergence and spread of AMR are propelled by multifaceted factors, including inappropriate antimicrobial use in human medicine and agriculture, inadequate infection control, environmental contamination, and weak regulatory frameworks. Socioeconomic determinants such as poverty, poor education, and limited healthcare access further exacerbate misuse and resistance, particularly in LMICs. Despite increased global recognition and the implementation of initiatives like the WHO Global Action Plan, persistent challenges remain in surveillance, measurement, and coordinated response. Many countries face infrastructural and operational limitations that result in fragmented and incomplete data, hindering effective policy development and intervention. AMR imposes significant clinical, economic, and social burdens, including increased morbidity and mortality, higher healthcare costs, reduced workforce productivity, and widening health inequities. Current response strategies emphasize antimicrobial stewardship, infection prevention and control, and multisectoral policy frameworks, yet disparities in implementation and resource allocation persist. Future priorities call for strengthening global surveillance, fostering innovation in antimicrobial development, enhancing diagnostic and stewardship technologies, and promoting integrated One Health approaches that address the interconnectedness of human, animal, and environmental health. Sustained investment, cross-sector collaboration, and global equity are essential to effectively mitigate the AMR crisis, preserve antimicrobial efficacy, and protect public health for future generations.